Intelligence · Clinical pipeline
Rare disease · Phase II
Rare disease programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Rare disease Phase II programs: NovaPharmaNews indexes 6 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
Pipeline programs
-
AXS-05 (dextromethorphan-bupropion)
Axsome Therapeutics
Treatment Resistant Depression
1 trial -
Almonertinib 110 MG
Chinese University of Hong Kong
Rare Tumor
1 trial -
Dextromethorphan-Bupropion
Axsome Therapeutics
Major Depressive Disorder (MDD)
1 trial -
Nintedanib,Dextromethorphan
The First People's Hospital of Lianyungang
Idiopathic Pulmonary Fibrosis (IPF)
1 trial -
Rapamune 1 mg/mL oral solution
Tour Hekla
Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported
1 trial -
WO42178
Hoffmann-La Roche
Persistent or Recurrent Rare Epithelial Ovarian Tumors
1 trial
Frequently asked questions
How many rare disease Phase II programs exist?
6 programs match both the therapeutic area and stage filters in our published index.